SPONSORED

Congress to consider marijuana reform in spring

Bipartisan momentum for cannabis reform

•• 6 Min
Congress to consider marijuana reform in spring

Democrats in Congress are preparing for a full package of initiatives aimed at decriminalizing marijuana that they intend to implement this spring.

The federal proposals aim to bring 21st century banking services to the nearly $ 18 billion industry and clear the criminal records of thousands of marijuana offenders.

"The growing bipartisan momentum for cannabis reform shows that Congress is poised for progress in 2022, and we are closer than ever to aligning our cannabis policies and laws with the American people," said Rep. Earl Blumenauer (D -Oreas). Earl Blumenauer (D-Ore.) And Barbara Lee (D-Calif.) Wrote a memo to the Congressional Cannabis Caucus on Thursday.

Nearly 70 percent of Americans - including about half of Republicans - support marijuana legalization, the memo said, citing a 2020 Gallup poll. Five states joined recreational cannabis legalization in the past year - New Mexico, New Jersey, Virginia and Connecticut - as well as a plethora of political ideas "in Congress aimed at ending the cannabis ban," lawmakers said.

The memo is a roadmap for dozens of draft laws aimed at redefining the role of the federal government in every aspect of the cannabis industry, with some actions gaining the backing of the GOP.

Bills such as the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, backed by Lee and Blumenauer, aim to remove cannabis from the Controlled Substance Act and erase the records of people convicted of using marijuana.

Other bills would encourage the development of a legal cannabis market in Washington D.C. Enable, enforce the legality of government cannabis programs and the ability to apply them to federal employees, and allow research into cannabis for the treatment of PTSD, while prohibiting retaliation by the veterans agency against doctors recommending the substance.

Another major bill, the SAFE Banking Act by Rep. Ed Perlmutter (D-Colo.), Would give the cannabis industry access to a range of financial services such as business loans, checking accounts, and credit card processing.

"Under current law, financial institutions that provide banking services to legitimate and licensed cannabis companies under state law are subject to criminal prosecution under several federal acts, such as' aiding and abetting '' a federal crime and money laundering," Perlmutter said in a statement to the bill.

This has forced the cannabis industry in most of the states where it is legal to do business almost entirely in cash - which run into the billions of dollars - leading to the occasional high-profile robbery and murder.

Then there are bills such as the two-party law on medical marijuana research, supported jointly by Blumenauer and MP Andy Harris (R-Md.). The move would lift restrictions on federal researchers studying marijuana "and ensure researchers have access to the same high-quality product that consumers use," the press release said.

Taken together, the draft laws show in broad outline what a liberalization policy for marijuana could look like: a modern, diverse, regulated industry with small producers - not dominated by giants like alcohol and tobacco.

"For states making progress on cannabis reform, we need to ensure that access to the growing cannabis industry is fair," the memo said. "In addition to investing in the communities hardest hit by the war on drugs, it is critical that states promote equal opportunities for participation in the cannabis industry, especially for people of color.

This coincides with statements from senators like the majority leader Charles Schumer (D-N.Y.). "We don't want the big boys to come in," Schumer told former New York MP Tremaine Wright in a panel discussion for the Black Enterprise news agency.

Given the long history of unequal enforcement of cannabis crimes "in communities like the one you represent in Brooklyn, which is where I'm from, it doesn't make sense for the big boys to come and make all the money," Schumer said.

The Senate plans to consider the bill this spring, according to Tom Rodgers of Carlyle Consulting, a lobbyist for cannabis legalization and Native American civil rights who is in contact with Schumer's office.

"We're going to have a big debate on cannabis next year, and they want that debate to be held before the mid-term elections," Rodgers said, adding that "virtually every committee in the Senate will receive a portion of this bill," including those committees that do deal with banking and criminal justice reform.

As House and Senate Democrats seek sweeping legislation, Rodgers said one element has been left out of the discussion: protecting Native Americans who use medical marijuana on tribal land.

A household in the land of Picuris Pueblo, New Mexico was raided by agents from the Bureau of Indian Affairs in November. They confiscated an estimated annual supply of marijuana from a man enrolled in the state medical marijuana program, The Associated Press reported.

A similar raid would not have been possible on non-Native American land, Rodgers said, because of New Mexico's medical marijuana program. Another measure by Blumenauer and MP Tom McClintock (R-Calif.), First passed by the House of Representatives in 2019 as part of the Grants Act, also prohibits any funding from the Justice Department for the enforcement of marijuana laws that violate the state's marijuana law.

A new version of the bill clarifies that it also applies to Native American tribes, meaning that marijuana markets run by tribes like the Oglala Sioux on Pine Ridge would be given the same powers as surrounding states.

But those amendments leave a huge loophole, Rodgers says, leaving Native American consumers and business owners vulnerable. The Bluemenauer changes only relate to actions by the Department of Justice, which delegates its powers to the states, according to Rodgers. The Bureau of Indian Affairs is subordinate to the Home Office, and the tribal areas it administers are federal - "domestic dependent nations," as the law has long termed it.

"Native Americans - First Americans - do not want to be treated unequal, unfavorably and disproportionately again when it comes to the application of this country's laws and services," Rodgers said.

Much of the pressure for reform comes from both sides. On Thursday the Reps. Dave Joyce, R-Ohio and Don Young, R-Alaska wrote to Biden and Vice President Harris urging a change in the strictness with which cannabis is listed or "classified" under federal controlled substances law to distinguish it from "far more dangerous drugs like fentantly, morphine, methadone and cocaine".

The restrictions imposed by marijuana being a Schedule 1 drug, Joyce said, "puts the United States way behind many of our international partners and scientific competitors," from Ireland and the UK to South Korea and Israel.

"In the interests of researchers, health professionals, and patients in the United States who continue to lose access to life-saving therapies and data every day that #cannabis remains overcontrolled," Joyce wrote on Twitter, "I'll keep asking."

CannabisUSAlegalization

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.